Early ultrasound evaluation identifies excellent responders to neoadjuvant systemic therapy among patients with triple‐negative breast cancer
Beatriz E. Adrada(The University of Texas MD Anderson Cancer Center), Gaiane M. Rauch(The University of Texas MD Anderson Cancer Center), Marion E. Scoggins(The University of Texas MD Anderson Cancer Center), Lumarie Santiago(Nektar Therapeutics (United States)), Jennifer K. Litton(The University of Texas MD Anderson Cancer Center), Jason B. White(The University of Texas MD Anderson Cancer Center), Alastair M. Thompson(Baylor College of Medicine), Stacy L. Moulder(The University of Texas MD Anderson Cancer Center), Rosalind P. Candelaria(The University of Texas MD Anderson Cancer Center), Tanya W. Moseley(The University of Texas MD Anderson Cancer Center), Vicente Valero(The University of Texas MD Anderson Cancer Center), Wei Yang(Shanghai Jiao Tong University), Gary J. Whitman(The University of Texas MD Anderson Cancer Center), Elizabeth E. Ravenberg(Eli Lilly (United States)), Peng Wei(Creighton University)
Cited by 23
Related Papers
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies
|Human Molecular Genetics|2014|1.2k
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|1.1k
Breast Cancer Before Age 40 Years
|Seminars in Oncology|2009|795
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017
|Journal of the National Comprehensive Cancer Network|2016|660